Our study further found that treatment with ML385 or Nrf2 siRNA abolished the inhibitory effect of PTA on cardiomyocyte pyroptosis, indicating that PTA exerts its protective effect against pathological cardiac hypertrophy by activating the Nrf2 signaling pathway to suppress NLRP3 inflammasome activation and pyroptosis. Here, NFE2L2 is linked to cardiac hypertrophy.